TITLE

Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring

AUTHOR(S)
Fink, Douglas L; Bloch, Edward
PUB. DATE
October 2013
SOURCE
International Journal of STD & AIDS;Oct2013, Vol. 24 Issue 10, p831
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
We present the first case report in the UK of acute liver failure caused by efavirenz therapy culminating in liver transplantation. A 26-year-old Zimbabwean woman commenced emtricitabine, tenofovir and efavirenz (Atripla) in December 2011. Her liver function tests at baseline and at 20 days after initiating antiretroviral therapy were normal. At three months of therapy her blood tests haemolysed and were not processed. She had previously missed follow-up appointments and on this occasion failed to return for repeat tests. She was not seen again until after six months of antiretroviral therapy when she presented to her general practitioner with acute liver failure. Her condition deteriorated and she required liver transplantation. She recovered well and re-started antiretroviral therapy to good effect. The case illustrates the value of routine monitoring after initiating antiretroviral therapy and the fundamental importance of engaging patients in long-term management to ensure safe treatment.
ACCESSION #
90310730

 

Related Articles

  • Efavirenz/emtricitabine/tenofovir disoproxil fumarate: Acute liver failure: case report.  // Reactions Weekly;Dec2013, Issue 1481, p17 

    The article presents a case study of a 26-year-old woman who was diagnosed with acute liver failure while receiving efavirenz/emtricitabine/tenofovir disoproxil fumarate for a HIV infection.

  • Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Wyen, Christoph; Hendra, Heidy; Siccardi, Marco; Platten, Martin; Jaeger, Hans; Harrer, Thomas; Esser, Stefan; Bogner, Johannes R.; Brockmeyer, Norbert H.; Bieniek, Bernhard; Rockstroh, Juergen; Hoffmann, Christian; Stoehr, Albrecht; Michalik, Claudia; Dlugay, Verena; Jetter, Alexander; Knechten, Heribert; Klinker, Hartwig; Skaletz-Rorowski, Adriane; F√§tkenheuer, Gerd // Journal of Antimicrobial Chemotherapy (JAC);Sep2011, Vol. 66 Issue 9, p2092 

    Objectives Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR)...

  • Oxidative stress induced by chronic administration of Efavirenz on the intracranial visual relay centers of adult Wistar rats. Adjene, J. O.; Avbunudiogba, J. A.; Igbigbi, P. S. // Biology & Medicine;Oct-Dec2011, Vol. 3 Issue 5, p16 

    The biochemical effects of chronic administration of efavirenz commonly used as part of highly active antiretroviral therapy (HAART) for the treatment of Human Immunodeficiency Virus (HIV) type-1 on the intracranial visual relay centres (namely superior colliculus and lateral geniculate body) of...

  • HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects. Mukonzo, Jackson K.; Nanzigu, Sarah; Rekig, Dinko; Waako, Paul; R√∂shammar, Daniel; Ashton, Michael; Ogwal-Okeng, Jasper; Gustafsson, Lars L.; Aklillu, Eleni // Clinical Pharmacokinetics;2011, Vol. 50 Issue 8, p531 

    Background: Pharmacokinetic studies of antiretroviral drugs are often conducted in adult healthy subjects, and the results are extrapolated to HIV/AIDS patients. HIV/AIDS, however, is known to cause morphological and physiological changes that may alter the pharmacokinetics of antiretroviral...

  • The Male Genital Tract Is Not a Pharmacological Sanctuary From Efavirenz. Avery, L. B.; Bakshi, R. P.; Cao, Y. J.; Hendrix, C. W. // Clinical Pharmacology & Therapeutics;Jul2011, Vol. 90 Issue 1, p151 

    Many antiretroviral (ARV) drugs have large blood plasma-to-seminal plasma (BP/SP) concentration ratios. Concern exists that these drugs do not adequately penetrate the male genital tract (MGT), resulting in the MGT becoming a 'pharmacological sanctuary' from these agents, with ineffective MGT...

  • Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report. van Ramshorst, Mette S.; Kekana, Magdeline; Struthers, Helen E.; McIntyre, James A.; Peters, Remco P. H. // BMC Pediatrics;2013, Vol. 13 Issue 1, p1 

    Background: Prepubertal gynecomastia is a rare condition and most frequently classified as idiopathic. In HIV-infected adults gynecomastia is a recognised but infrequent side-effect of antiretroviral treatment (ART) and mostly attributed to efavirenz use. Gynecomastia should be distinguished...

  • Once-Daily Pill Yields Higher ART Adherence.  // Infectious Disease Alert;Apr2011, Vol. 30 Issue 7, p81 

    The article discusses a research study on the one pill, once-daily regimen made up of a combination of efavirenz, emcitrabine and tenofovir in achieving high aderence to antiretroviral therapy (ART). Individuals from single room occupancy (SRO) hotels, free meal programs and homeless shelters...

  • Tenofovir/Emtricitabine/Efavirenz Plus Rosuvastatin Decrease Serum Levels of Inflammatory Markers More Than Antiretroviral Drugs Alone in Antiretroviral Therapy-Naive HIV-Infected Patients. Calza, Leonardo; Vanino, Elisa; Salvadori, Caterina; Manfredi, Roberto; Colangeli, Vincenzo; Cascavilla, Alessandra; Di Bari, Maria Assunta; Motta, Roberto; Viale, Pierluigi // HIV Clinical Trials;Jan/Feb2014, Vol. 15 Issue 1, p1 

    Objectives: Statins are lipid-lowering drugs that exhibit anti-Inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. Design: To assess the anti-inflamatory effects of statins in HIV-infected patients, because...

  • Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1. Eric S. Daar, MD; Camlin Tierney, PhD; Margaret A. Fischl, MD; Paul E. Sax, MD; Katie Mollan, MS; Chakra Budhathoki, PhD;; Godfrey, Catherine; Jahed, Nasreen C.; Myers, Laurie; Katzenstein, David; Farajallah, Awny; Rooney, James F.; Pappa, Keith A.; Woodward, William C.; Patterson, Kristine; Bolivar, Hector; Benson, Constance A.; Collier, Ann C. // Annals of Internal Medicine;4/5/2011, Vol. 154 Issue 7, p445 

    Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective: To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics